Cellid, Co., Ltd.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.cellid.co.kr

Country

South Korea

Exchange

KOSDAQ

Founded 2006Seoul, South Korea

Cellid develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection.

Its portfolio also includes BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen, and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Founded in 2006, Cellid is headquartered in Seoul, South Korea.

Key Stats

52-Week Range

₩973.00₩4760.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.